CANF Valuation

Can Fite Biopharma Ltd

Add to Watchlist

Advanced Chart

0.980

-0.03(-2.970%)1D

Overview
Forecast
Valuation
Earnings

CANF Relative Valuation

CANF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CANF is overvalued; if below, it's undervalued.

Historical Valuation

Can Fite Biopharma Ltd (CANF) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -0.77. The fair price of Can Fite Biopharma Ltd (CANF) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 0.98 USD , Can Fite Biopharma Ltd is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：0.98

Fair

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

568.06

P/B

Median3y

241.79

Median5y

146.52

-53.40

FCF Yield

Median3y

-43.48

Median5y

-32.54

Competitors Valuation Multiple

The average P/S ratio for CANF's competitors is 5.17, providing a benchmark for relative valuation. Can Fite Biopharma Ltd Corp (CANF) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -21.32%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CANF.A

Can Fite Biopharma Ltd

Loss

Average P/S: 5.17

-21.32%